Term ends Mar 26, 2030 · High confidence
20-year base term ends Apr 14, 2029
Held by Grifols Therapeutics LLC
Filed Jun 3, 2014 as application 14/294,460 · Granted Aug 8, 2017
Base term plus 346 days of patent term adjustment (USPTO delay)
Today
2009
2030
Clock starts
Apr 14, 2009
Apr 14, 2009
Term ends
Mar 26, 2030
Mar 26, 2030
Granted
Aug 8, 2017
Aug 8, 2017
base term
patent term adjustment
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
346
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,772,461, to Mar 26, 2030. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 346 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 14, 2009, when application PCT/US2009/040499, the earliest non-provisional in its chain, was filed (this one was filed Jun 3, 2014) | Apr 14, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +346 days, USPTO patent term adjustment record | Mar 26, 2030 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,772,461) | resolves to Mar 26, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 26, 2030 | High confidence |
This family
| US 8,772,461 | In force Oct 2031 | Oct 2031 |
| US 9,725,501 | this patent Mar 2030 | Mar 2030 |
2 of 3 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
The 40 most recent of 68 recorded documents are shown; the 28 earliest are not. Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 1, 2021 reel/frame not recorded | The Bank of New York Mellon, London Branch | Biomat USA, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51047/0139 |
| Dec 1, 2021 reel/frame not recorded | The Bank of New York Mellon, London Branch | Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51047/0139 |
| Dec 7, 2021 Reel 58350, frame 980 | European Investment Bank | Biomat USA, Inc.; Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51021/0593 |
| Dec 7, 2021 Reel 58351, frame 64 | European Investment Bank | Biomat USA, Inc.; Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51024/0453 |
| Dec 7, 2021 Reel 58518, frame 524 | European Investment Bank | Biomat USA, Inc.; Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51024/0317 |
| Dec 7, 2021 reel/frame not recorded | European Investment Bank | Biomat USA, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51021/0593 |
| Dec 7, 2021 reel/frame not recorded | European Investment Bank | Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51021/0593 |
| Dec 7, 2021 reel/frame not recorded | European Investment Bank | Biomat USA, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51024/0453 |
| Dec 7, 2021 reel/frame not recorded | European Investment Bank | Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51024/0453 |
| Dec 7, 2021 reel/frame not recorded | European Investment Bank | Biomat USA, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51024/0317 |
| Dec 7, 2021 reel/frame not recorded | European Investment Bank | Talecris Plasma Resources, Inc. | Partial Release of Security Interest in Patents at Reel/Frame No. 51024/0317 |
| Dec 10, 2021 Reel 58480, frame 221 | Bank of America, N.A., as Collateral Agent | Biomat USA, Inc.; Talecris Plasma Resources, Inc. | Partial Release of Security Interest |
| Dec 10, 2021 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Biomat USA, Inc. | Partial Release of Security Interest |
| Dec 10, 2021 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Talecris Plasma Resources, Inc. | Partial Release of Security Interest |
| May 14, 2024 Reel 67409, frame 127 | Grifols Shared Services North America, Inc.; Grifols Therapeutics LLC; Grifols Biologicals LLC; Grifols Worldwide Operations USA, Inc.; Grifols USA, LLC | The Bank of New York Mellon, London Branch | Security Interest |
| Apr 15, 2026 Reel 75329, frame 824 | The Bank of New York Mellon, London Branch | Grifols Shared Services North America, Inc.; Grifols Therapeutics LLC (F/K/A Grifols Therapeutics, Inc.); Grifols Biologicals LLC (F/K/A Grifols Biologicals, Inc.); Grifols Worldwide Operations USA, Inc.; Grifols USA, LLC; Biomat USA, Inc.; Talecris Plasma Resources, Inc. | Release of Security Interest |
| Apr 15, 2026 Reel 75416, frame 718 | European Investment Bank | Grifols Shared Services North America, Inc.; Grifols Therapeutics LLC (F/K/A Grifols Therapeutics, Inc.); Grifols Biologicals LLC (F/K/A Grifols Biologicals, Inc.); Biomat USA, Inc.; Grifols Worldwide Operations USA, Inc.; Grifols USA, LLC; Talecris Plasma Resources, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Grifols Shared Services North America, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Grifols Therapeutics LLC (F/K/A Grifols Therapeutics, Inc.) | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Grifols Biologicals LLC (F/K/A Grifols Biologicals, Inc.) | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Grifols Worldwide Operations USA, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Grifols USA, LLC | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Biomat USA, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | The Bank of New York Mellon, London Branch | Talecris Plasma Resources, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Grifols Shared Services North America, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Grifols Therapeutics LLC (F/K/A Grifols Therapeutics, Inc.) | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Grifols Biologicals LLC (F/K/A Grifols Biologicals, Inc.) | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Biomat USA, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Grifols Worldwide Operations USA, Inc. | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Grifols USA, LLC | Release of Security Interest |
| Apr 15, 2026 reel/frame not recorded | European Investment Bank | Talecris Plasma Resources, Inc. | Release of Security Interest |
| May 21, 2026 Reel 75614, frame 936 | Bank of America, N.A., as Collateral Agent | Grifols Shared Services North America, Inc.; Grifols Therapeutics LLC (Formerly Known as Grifols Therapeutics, Inc.); Grifols Biologicals LLC (Formerly Known as Grifols Biologicals, Inc.); Biomat USA, Inc.; Grifols USA, LLC; Grifols Worldwide Operations USA, Inc.; Talecris Plasma Resources, Inc. | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Grifols Shared Services North America, Inc. | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Grifols Therapeutics LLC (Formerly Known as Grifols Therapeutics, Inc.) | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Grifols Biologicals LLC (Formerly Known as Grifols Biologicals, Inc.) | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Biomat USA, Inc. | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Grifols USA, LLC | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Grifols Worldwide Operations USA, Inc. | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Talecris Plasma Resources, Inc. | Release of Security Interest in Patents, Recorded on December 10, 2021 at Reel 058480 Frame 0221 |
| May 21, 2026 Reel 75624, frame 7 | Grifols Shared Services North America, Inc.; Grifols Therapeutics LLC (Formerly Known as Grifols Therapeutics, Inc.) | Bank of America, N.A., as Collateral Agent | Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2030
Term ends Mar 26, 2030. Maintenance fees still fall due before then
Note
The 346 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,772,461, ends no earlier than this term, so it caps nothing.
Citations
9
later US patents cite this one
That is above the median of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.